Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
177 hedge funds and large institutions have $3.73B invested in Karuna Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 19 closing their positions.
97% more call options, than puts
Call options by funds: $28.7M | Put options by funds: $14.6M
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
16% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 58
4% more funds holding
Funds holding: 171 → 177 (+6)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
2% less capital invested
Capital invested by funds: $3.83B → $3.73B (-$93.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.9M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$103M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$22.5M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$18.6M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$17.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.9M |
KRTX Hedge Fund Activity: Q1 2022 in Review
177 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2022, worth a combined $3.73B — down 2.4% from $3.83B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KRTX positions and 19 closed out — a net gain of 6 holders — while 67 added to existing stakes and 58 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $31.7M. The largest seller was Federated Hermes, cutting an estimated $103M.
- 177 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2022, up from 171 in Q4 2021.
- Funds reported $3.73B of Karuna Therapeutics, Inc. Common Stock stock for Q1 2022, down 2.4% quarter-over-quarter.
- 25 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2022 and 19 closed out, a net change of +6 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q1 2022 was Adage Capital Partners, an estimated $31.7M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2022 was Federated Hermes, an estimated $103M sold.
Based on aggregated 13F filings for Q1 2022.